AKAP12 and prostate cancer: In the five types of controversial cancers (NSCLC, bladder cancer, prostate cancer, colorectal cancer, pancreatic cancer), several reports showed miR-186 served as an oncomir by suppressing targets PTEN, PPM1B, RETREG1, AKAP12, or NR5A2.